Caribou Biosciences, Inc.

NasdaqGS:CRBU 株式レポート

時価総額：US$164.6m

Caribou Biosciences 将来の成長

Future 基準チェック /26

Caribou Biosciencesの収益は年間21.3%で減少すると予測されていますが、年間収益は年間44.4%で増加すると予測されています。EPS は年間 減少すると予測されています。自己資本利益率は 3 年後に-98.1% 15.2%なると予測されています。

主要情報

-21.3%

収益成長率

-15.23%

EPS成長率

Biotechs 収益成長24.9%
収益成長率44.4%
将来の株主資本利益率-98.15%
アナリストカバレッジ

Good

最終更新日11 Jun 2026

今後の成長に関する最新情報

Recent updates

分析記事 • May 13

Need To Know: Analysts Are Much More Bullish On Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenues

Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Nov 03

Caribou Biosciences: A Much Anticipated Data Readout Does Not Quite Get My Buy

Summary Caribou Biosciences has recently reported some very exciting early data, with more in their allogeneic CAR T-cell pipeline guided by the end of the year. Encouraging myeloma data point to possible best-in-class anti-BCMA cell therapy, which could serve a very viable niche. Although there is sufficient cash to reach another data readout, I am affirming a "Hold" for CRBU here based on the need for more proving of these programs. Read the full article on Seeking Alpha
Seeking Alpha • Jan 02

Caribou Biosciences: CB-010 And Other CAR-Ts Pressing Forward Despite Initial Data

Summary Caribou Biosciences, Inc. data from phase 1 ANTLER study, using CB-010 to target 2nd-line LBCLC patients and prior CD19 treated patients with partial matched HLA, expected in the 1st half of 2025. The global B-Cell Lymphoma treatment market size is expected to reach $13.14 billion by 2030. Dose-escalation data from the phase 1 CaMMouflage trial, using CB-011 for the targeting of patients with relapsed/refractory Multiple Myeloma, expected 1st half of 2025. CRBU's initiation of the phase 1 GALLOP trial, using CB-010 for the treatment of patients with lupus nephritis and extrarenal lupus, expected in the upcoming months. Read the full article on Seeking Alpha
分析記事 • Dec 31

Here's Why Caribou Biosciences (NASDAQ:CRBU) Must Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Nov 05

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares Bounce 25% But Its Business Still Trails The Industry

Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shareholders would be excited to see that the share price has had a great...
Seeking Alpha • Sep 30

Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing

Summary Caribou Biosciences focuses on allogeneic CAR-T therapies for hematological cancers and autoimmune diseases, leveraging its unique chRDNA genome-editing technology. In my view, CRBU's chRDNA platform offers precise genome editing and could potentially outperform competitors like Allogene Therapeutics. CRBU's flagship candidate, CB-010, shows promising results in Phase 1 trials for large B cell lymphoma, with long-term complete response rates. The FDA's Fast Track Designation for CB-010 and CB-012 supports optimism, but definitive Phase 3 data is needed to corroborate CRBU's still speculative IP. CRBU's valuation is significantly lower than its peers, but it has sufficient resources until 2H2026. Thus, I rate it a "buy" after appreciating by over 20% since my previous article. Read the full article on Seeking Alpha
分析記事 • Sep 06

Here's Why We're Watching Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Jul 26

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

Those holding Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shares would be relieved that the share price has rebounded 39...
Seeking Alpha • Jul 03

Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential

Summary Caribou Biosciences develops allogeneic therapies using CRISPR technology, focusing on hematologic cancers and autoimmune diseases. CB-010, CB-011, and CB-012 are in Phase 1 clinical trials, with CB-010 showing promising results for B cell non-Hodgkin lymphoma. Evercore downgraded CRBU’s stock due to high COGS concerns, but its superior efficacy and safety might justify higher prices. CRBU’s CB-010 achieved a 92% ORR and favorable safety compared to competitors Yescarta and Kymriah. Despite early-stage risks, CRBU’s undervaluation and large TAM present a compelling speculative buy opportunity. Read the full article on Seeking Alpha
分析記事 • Jun 05

Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding

To the annoyance of some shareholders, Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shares are down a considerable 43% in...
Seeking Alpha • Apr 18

Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

Summary Caribou Biosciences, Inc. is expected to produce results from phase 1 ANTLER study, using CB-010 for the treatment of 2nd-line large B-cell lymphoma patients, at medical meeting Q2 of 2024. Initial dose escalation data from the phase 1 ANTLER study indicated that CB-010 was able to generate a 90% objective response rate for patients with relapsed or refractory LBCL. Clearance was given by the FDA to initiate a phase 1 study using CB-010 for patients with lupus nephritis and extrarenal lupus; Trial initiation expected by the end of 2024. Initial dose-escalation data from the phase 1 CaMMouflage study, using CB-011 for the treatment of patients with relapsed or refractory multiple myeloma patients by end of 2024. Read the full article on Seeking Alpha
分析記事 • Apr 17

More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%

Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shareholders that were waiting for something to happen have been dealt a blow...
分析記事 • Feb 15

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up

Despite an already strong run, Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shares have been powering on, with a gain of...
Seeking Alpha • Feb 01

Caribou Biosciences: Under The Radar With Catalysts Approaching

Summary CRBU has provided regulatory and clinical updates in the past couple of months, but hasn't rallied quite like other biotech names. CRBU achieved alignment with the FDA on the comparator arm for its pivotal study of CB-010, and confirmed further data from the phase 1 ANTLER study in Q2'24. CRBU has progressed to the third dose level of CB-011 in the CaMMouflage study, and confirmed initial data are expected by year-end 2024. Read the full article on Seeking Alpha
分析記事 • Jan 10

Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Nov 18

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues

Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shareholders are no doubt pleased to see that the share price has bounced 28...
分析記事 • Feb 24

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Oct 12

Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability

Summary Caribou Biosciences' early data was good, but not that durable. However, this was the lowest dose cohort, and safety was manageable. If a higher dose, now ongoing, produces a durable response, this stock will likely go up. Caribou Biosciences (CRBU), founded by CRISPR pioneer Jennifer Doudna, is another CAR-T stock that has been down for months on end. Since my last coverage almost exactly a year ago, the stock is down 50%. Not a lot has happened with the company since then - which is one of the many reasons this stock is a laggard. Last year, we saw how the clinical hold on Allogene (ALLO) caused CRBU stock to falter. In October last year, the FDA placed a clinical hold on all 5 programs of Allogene following a report of a chromosomal abnormality in ALLO-501A CAR T cells in a patient treated in the ALPHA2 study. Per the company: The single case involves a patient with Stage IV transformed follicular lymphoma and c-myc rearrangement whose cancer was refractory to two prior lines of immune-chemotherapy and additional radiation therapy. The patient could not receive an autologous CD19 CAR T cell therapy due to manufacturing failure associated with inadequate expansion of autologous CAR T cells. Following infusion of ALLO-501A, the patient experienced Grade 1 CRS and Grade 2 ICANS, which required a course of high dose steroid therapy. The patient subsequently developed progressive pancytopenia and a bone marrow biopsy showed aplastic anemia and the presence of ALLO-501A CAR T cells with the chromosomal abnormality. Early translational data showed that the CAR T cells expanded, peaking on Day 28, and undergoing contraction thereafter. The patient had a partial response to ALLO-501A and subsequently underwent allogeneic stem cell transplantation. Prolonged cytopenia requiring rescue stem cell transplantation has been reported in autologous CAR T therapies. This has a direct bearing on Caribou. While it uses a different gene editing technology from Allogene - chRDNA, a type of Crispr, versus the latter’s TALEN, an older but more precise technology - there are enough similarities to warrant caution. The main concern is the TRAC (T Cell Receptor Alpha Constant) edit, which occurs under both programs, and which caused the pancytopenia in the Allogene patient. Even though the tech is different, these are the same edits. In January, the FDA lifted the clinical hold for Allogene, and the collective gene editing space heaved a sigh of relief. What they said: Investigations concluded that the chromosomal abnormality was unrelated to TALEN® gene editing or Allogene’s manufacturing process and had no clinical significance. The abnormality was not detected in any manufactured AlloCAR T product or in any other patient treated with the same ALLO-501A lot. The abnormality occurred in the patient after the cell product was administered. It involved regions of the T cell receptor and immunoglobulin genes known to undergo rearrangement as part of the T cell or B cell maturation process. I believe the FDA let it slide because there was just this one patient. Otherwise, there would have been further investigation - unrelated or not. In May, Caribou posted early data from the lowest dose cohort of lead candidate CB-010 in a phase 1 trial in penta- or more refractory NHL patients, and there was a strong drug response seen in patients, with all 5 of the 5 patients showing an overall response rate of 100%, while 80% of patients had no detectable evidence of cancer, i.e., they had a CR or complete response. The data was so good that the stock went up 30% despite some nagging safety issues - specifically, Grade 3 or 4 treatment emergent adverse events (TEAEs) developed in 5 of 6 patients.
分析記事 • Sep 16

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

業績と収益の成長予測

NasdaqGS:CRBU - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/202835-182N/AN/A4
12/31/202730-157N/AN/A5
12/31/202626-125N/AN/A6
3/31/202611-133-102-101N/A
12/31/202511-148-112-111N/A
9/30/20259-157-128-126N/A
6/30/20259-164-136-133N/A
3/31/202510-148-142-138N/A
12/31/202410-149-145-138N/A
9/30/202411-148-132-124N/A
6/30/202433-123-133-120N/A
3/31/202433-115-115-103N/A
12/31/202334-102-105-93N/A
9/30/202335-95-108-97N/A
6/30/202314-111-99-91N/A
3/31/202315-108-106-97N/A
12/31/202214-99-98-91N/A
9/30/202213-91-93-87N/A
6/30/202213-85-86-80N/A
3/31/202211-73-78-75N/A
12/31/202110-67-36-33N/A
9/30/20218-63-22-19N/A
6/30/20215-50-14-13N/A
3/31/202112-38-4-4N/A
12/31/202012-34-35-33N/A
12/31/20196-23N/A-32N/A

アナリストによる今後の成長予測

収入対貯蓄率: CRBU今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CRBU今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CRBU今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CRBUの収益 ( 44.4% ) US市場 ( 12.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: CRBUの収益 ( 44.4% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CRBU 3 年以内に赤字になると予測されています。

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/06/12 21:34
終値2026/06/12 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Caribou Biosciences, Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10

アナリスト機関
Alec StranahanBofA Global Research
Leah Rush CannBrookline Capital Markets
Yigal NochomovitzCitigroup Inc